IN8bio reports 100% complete remission in INB-100 Phase 1 leukemia trial; RP2D selected

IN8BIO, INC.

100% of evaluable patients (n=7) in durable CR; one patient progression-free beyond 3 years.
Gamma-delta T cells expanded 82.9x at Dose Level 2 vs. standard haploidentical HSCT at 60 days.
Dose Level 2 selected as recommended Phase 2 dose based on safety, tolerability, and expansion data.
No dose-limiting toxicities observed; all GvHD low-grade and steroid-responsive.
Conference call today at 10 a.m. ET; updated data expected at future medical meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.